PCSK9 and myocardial infarction: This systematic review will address the key questions surrounding the major research objectives: What is the effectiveness of PCSK9 inhibitors in reducing major adverse cardiovascular events, specifically myocardial infarction, stroke, and cardiovascular death, in the statin-intolerant population?